Literature DB >> 26901255

[Dilated cardiomyopathy: a dynamic disease - clinical course, reverse remodeling and prognostic stratification].

Marco Merlo1, Marta Gigli1, Stefano Poli1, Davide Stolfo1, Francesca Brun1, Gerardina Lardieri1, Bruno Pinamonti1, Massimo Zecchin1, Alberto Pivetta1, Giancarlo Vitrella1, Andrea Di Lenarda1, Gianfranco Sinagra1.   

Abstract

Dilated cardiomyopathy (DCM) is a relatively rare primary heart muscle disease with genetic or post-inflammatory etiology. In the last decade, the incidence and prevalence of the disease have significantly increased as a consequence of an earlier diagnosis supported by extensive familial screening programs and by the improvement in diagnostic techniques. Moreover, current therapeutic strategies have deeply modified the prognosis of DCM with a dramatic reduction in mortality. A significant number of patients with DCM present an impressive response to pharmacological and non-pharmacological therapy in terms of left ventricular reverse remodeling (reduction in ventricular size with improvement of systolic function), which confers a more favorable prognosis in the long term. However, the identification of patients with an increased likelihood of improvement after therapeutic optimization remains a challenging issue; in particular the assessment of arrhythmic risk carries important implications. Finally, the long-term follow-up of patients showing a significant left ventricular functional recovery under optimal treatment is still poorly known. Hence, the aim of the present review is to provide an insight into the clinical evolution/long-term follow-up of DCM, which should be actually considered a dynamic process rather than a static and chronic disease. Left ventricular reverse remodeling should be considered a key therapeutic goal, mostly associated with a long-standing recovery, but cannot be considered the expression of permanent "healing", confirming the need for a systematic and careful follow-up over time in this setting.

Entities:  

Mesh:

Year:  2016        PMID: 26901255     DOI: 10.1714/2140.23184

Source DB:  PubMed          Journal:  G Ital Cardiol (Rome)        ISSN: 1827-6806


  4 in total

1.  Development and verification of the nomogram for dilated cardiomyopathy gene diagnosis.

Authors:  Li-Qiang Zhou; Chuan Liu; Yeqing Zou; Zhi-Qing Chen
Journal:  Sci Rep       Date:  2022-05-26       Impact factor: 4.996

2.  Fifteen-year mortality and prognostic factors in patients with dilated cardiomyopathy: persistent standardized application of drug therapy and strengthened management may bring about encouraging change in an aging society.

Authors:  Xiao-Rong Xu; Meng-Meng Han; Yi-Zhen Yang; Xin Wang; Dong-Yan Hou; Xian-Chen Meng; Hua Wang; Wen-Shu Zhao; Lin Zhang; Lin Xu
Journal:  J Geriatr Cardiol       Date:  2022-05-28       Impact factor: 3.189

3.  A systematic review of randomised controlled trials examining the therapeutic effects of adult bone marrow-derived stem cells for non-ischaemic dilated cardiomyopathy.

Authors:  Yi Lu; Yiqin Wang; Menglu Lin; Jiale Zhou; Zi Wang; Meng Jiang; Ben He
Journal:  Stem Cell Res Ther       Date:  2016-12-09       Impact factor: 6.832

4.  Integrated Analysis of Hub Genes and miRNAs in Dilated Cardiomyopathy.

Authors:  Kai Huang; Shuyan Wen; Jiechun Huang; Fangrui Wang; Liewen Pang; Yiqing Wang; Xiaotian Sun
Journal:  Biomed Res Int       Date:  2020-09-15       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.